• Ernexa reported new preclinical safety results for ERNA-101, supporting a planned IND filing in Q4 2026.
• Results were presented now, covering repeat-dose toxicology, tumorigenicity, biodistribution, and a single-dose cytokine release assessment.
• Studies showed no treatment-related safety findings, with no evidence of acute cytokine release in the single-dose evaluation.
• Tumorigenicity testing showed no teratoma formation through a six-month in-life phase; final pathology review remains in progress.
• Company plans a first-in-human study in platinum-resistant ovarian cancer, with initial clinical data expected in Q4 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ernexa Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609300832PRIMZONEFULLFEED9836905) on September 30, 2026, and is solely responsible for the information contained therein.